Dr. David Sinclair

But the idea is that this doxycycline will turn on these three genes for about eight weeks.

And the doctor in charge of the clinical trial, one of them's at Harvard, a good friend of mine, he'll measure the vision of the first patient before the treatment and, of course, regular intervals.

And if all goes well, because we're treating patients, not healthy volunteers, in the first trial, we should know within either one or two patients if it works.

Because we're not drawing a graph.

It's either going to work or it isn't.

The patient gets better eyesight or they don't.

So by this time next year, we will know if it works or not, maybe even sooner.

But publicly, we may know if this works.

And if it works, the eye is just the beginning.

So the first disease to treat is glaucoma, pressure in the eye.

There's also a stroke in the eye, which is becoming more prevalent in the world because of the ozempic and other weight loss drugs.

And people go blind overnight.

And there's nothing that you can do for those patients.

They're blind.

And their other eye can go a few months later.

It's very scary for them.

These are young people.

A friend of mine had it happen.

It's pretty common these days, about 30,000 people each year in the US alone.

But these two diseases are the beginning.